129872-81-7

Basic information

• Product Name: 2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine
• Synonyms: 2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine;5H-Pyrrolo[3,2-d]pyrimidine,2,4-dichloro-5-methyl-
• CAS NO: 129872-81-7
• Molecular Formula: C₇H₅Cl₂N₃
• Molecular Weight: 202.044
• Mol File: 129872-81-7.mol

Chemical Properties

• Appearance: /
• Density: 1.6g/cm³
• Refractive Index: 1.7
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine(129872-81-7)
• EPA Substance Registry System: 2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine(129872-81-7)

Safety Data

• Hazardous Substances Data: 129872-81-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine is used as a pharmaceutical candidate for its anti-proliferative and anti-cancer properties. It has demonstrated promising results in inhibiting the growth of certain types of cancer cells, making it a potential agent for cancer treatment.
Used in Drug Development for Parasitic Infections:
In the field of parasitic infections, 2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine is used as a potential drug candidate for the treatment of malaria. Its unique structure and pharmacological properties have shown potential in developing new drugs to combat this disease.
Used in Medicinal Chemistry Research:
2,4-Dichloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine is utilized as a subject of research in medicinal chemistry to explore its potential applications and further understand its pharmacological properties. This research aims to enhance drug discovery and development processes.

InChI:InChI=1/C7H5Cl2N3/c1-12-3-2-4-5(12)6(8)11-7(9)10-4/h2-3H,1H3

Upstream product

• 77-78-1 dimethyl sulfate 
• 63200-54-4 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 
• 66-27-3 Methyl methanesulfonate 
• 74-88-4 methyl iodide 

Downstream Products

• 1375301-63-5 4-(2-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)morpholine 
• 914494-96-5 4-(2-(4-cyanophenylamino)-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile 
• 1620147-19-4 2-chloro-5-methyl-4-(4-(trifluoromethoxy)phenyl)-5H-pyrrolo[3,2-d]pyrimidine 

Relevant articles and documents

Double-ring heterocyclic amines Hedgehog signal pathway inhibitor

The invention relates to the field of biological medicine, and concretely relates to bicyclic heterocyclic amine compounds, and the compounds are a new Hedgehog inhibitor and pharmaceutically acceptable salts shown as a general formula (I). The compounds can be used as a Hedgehog signal conduction inhibitor applied to multiple medical applications.

PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.

Pyrrolo pyrimidine derivate and application thereof

The invention belongs to the field of medicinal chemistry, and specifically relates to a pyrrolo pyrimidine derivate. The structure of the pyrrolo pyrimidine derivate is shown as formula (I), wherein X and Y independently represent N, O and S or SO; R1 is

INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF

The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS

A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailm

Five-membered heteroaromatic ring fused-pyrimidine derivatives: Design, synthesis, and hedgehog signaling pathway inhibition study

A series of novel five-membered heteroaromatic ring fused-pyrimidine derivatives including purines, pyrrolo[2,3-d]pyrimidines, pyrrolo[3,2-d] pyrimidines, thieno[2,3-d]pyrimidines, thieno[3,2-d]pyrimidines and furo[3,2-d]pyrimidines have been identified to be potent inhibitors of hedgehog signaling pathway. The synthesis and SAR of these compounds are described. Among this new series of hedgehog signaling pathway inhibitors, most compounds exhibited significant inhibitory activity compared to vismodegib, indicating that the five-membered heteroaromatic ring fused-pyrimidines stand out as encouraging scaffolds among the currently reported structural skeletons for hedgehog signaling pathway inhibitors, deserving more exploration and further investigation.

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

AROMATIC COMPOUND

An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

ALICYCLIC HETEROCYCLIC COMPOUND

An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

Direct C-Glycosylation of Guanine Analogues: The Synthesis and Antiviral Activity of Certain 7- and 9-Deazaguanine C-Nucleosides

C-Glycosylation of two guanine analogues, 9-deaza- and 7-deazaguanine, has been achieved under Friedel-Crafts conditions, providing a direct synthetic route to 9-deazaguanosine (4; 2-amino-7-β-D-ribofuranosyl-5H-pyrrolopyrimidin-4(3H)-one) and 8-β-